Press releases

22 Sep 2022

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

20 Sep 2022

European Medicine Agency Accepts Marketing Authorization Applications for Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis

9 Sep 2022

Disposal of own shares

9 Sep 2022

ASBMR 2022: 3D modelling of hip DXA scans in postmenopausal women with osteoporosis reveals superior improvements in bone density of romosozumab versus controls

7 Sep 2022

New Three-Year BIMZELX[®]▼ (bimekizumab) Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis

1 Sep 2022

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Press releases

Press releases

Search Press releases

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

European Medicine Agency Accepts Marketing Authorization Applications for Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis

Disposal of own shares

ASBMR 2022: 3D modelling of hip DXA scans in postmenopausal women with osteoporosis reveals superior improvements in bone density of romosozumab versus controls

New Three-Year BIMZELX[®]▼ (bimekizumab) Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Choose a Country

UCB Belgium: A global hub of healthcare innovation

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Sustainability – Click here to learn more about our sustainable approach

UCBCares® - Discover what UCBCares® is about and the services they offer

Advancing Our Gene Therapy Journey

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant...

UCB completes sale of established brands and updates 2024 financial guidance

UCB completes sale of established brands and updates 2024 financial guidance

Half-year results 2024: strong start into UCB’s decade of growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

European Medicine Agency Accepts Marketing Authorization Applications for Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis

Disposal of own shares

ASBMR 2022: 3D modelling of hip DXA scans in postmenopausal women with osteoporosis reveals superior improvements in bone density of romosozumab versus controls

New Three-Year BIMZELX[®]▼ (bimekizumab) Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Choose a Country